DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Ponatinib
Ponatinib
A Phase II, Open-Label Study of Ponatinib, a Multi-Targeted Oral
Iclusig® (Ponatinib) 15 Mg and 45 Mg Tablets for Oral Use
Ponatinib Shows Potent Antitumor Activity in Small Cell Carcinoma of the Ovary Hypercalcemic Type (SCCOHT) Through Multikinase Inhibition Jessica D
The Effects of Combination Treatments on Drug Resistance in Chronic Myeloid Leukaemia: an Evaluation of the Tyrosine Kinase Inhibitors Axitinib and Asciminib H
Characteristics of Trials and Regulatory Pathways Leading to US Approval Of
Crenolanib Is a Selective Type I Pan-FLT3 Inhibitor
CML and Tyrosine Kinase Inhibitors – What Are the Cardiovascular Toxicities? Should Everyone Get an Ankle Brachial Index (ABI) Before Starting?
(FDA) Approved Bristol Myers Squibb's (Bms.Com) Br
Potent Activity of Ponatinib (AP24534) in Models of FLT3-Driven Acute Myeloid Leukemia and Other Hematologic Malignancies
Cancer Drug Costs for a Month of Treatment at Initial Food
Kinase Drug Discovery 20 Years After Imatinib: Progress and Future Directions
Targeted Cancer Therapies
Axitinib and Sorafenib Are Potent in Tyrosine Kinase Inhibitor Resistant
Update on Molecular Pathology and Role of Liquid Biopsy in Nonsmall Cell Lung Cancer
Targeting HER2 Aberrations in Non–Small Cell Lung Cancer with Osimertinib Shengwu Liu1, Shuai Li2,3, Josephine Hai1, Xiaoen Wang1, Ting Chen3, Max M
Ponatinib Inhibits Multiple Signaling Pathways Involved in STAT3 Signaling and Attenuates Colorectal Tumor Growth
Ponatinib Inhibits Polyclonal Drug-Resistant KIT Oncoproteins and Shows Therapeutic Potential in Heavily Pretreated Gastrointestinal Stromal Tumor (GIST) Patients
Repurposing Tyrosine Kinase Inhibitors to Overcome Multidrug Resistance in Cancer: a Focus on Transporters and Lysosomal Sequestration
Top View
Pdf Were Recorded Every 20 Ps
ATC/DDD Classification (Final)
Inhibitors of BRAF Dimers Using an Allosteric Site ✉ Xiomaris M
Cardiovascular Health During and After Cancer Therapy
Prescribing Information | ICLUSIG® (Ponatinib)
Ponatinib (Iclusig): National Drug Monograph
PF-114, a Potent and Selective Inhibitor of Native and Mutated BCR/ABL Is Active Against Philadelphia Chromosome-Positive (Ph+) Leukemias Harboring the T315I Mutation
SAFE HANDLING of HAZARDOUS DRUGS Updated 5/22/2020
Adult Antiemetic Management of Chemotherapy-Induced Nausea
Axitinib in Ponatinib-Resistant B-Cell Acute Lymphoblastic Leukemia Harboring a T315L Mutation
New Perspectives, Opportunities, and Challenges in Exploring the Human Protein Kinome Leah J
Kinase Inhibitors and Monoclonal Antibodies in Oncology: Clinical Implications
Oncology Therapy for the Generalist
And Axitinib-Induced Cell Death in BCR-ABL T315I-Containing
Combination Therapy with the CDK7 Inhibitor and the Tyrosine Kinase Inhibitor Exerts
Dasatinib Reversibly Disrupts Endothelial Vascular Integrity By
The Novel BCR-ABL and FLT3 Inhibitor Ponatinib Is a Potent Inhibitor of the MDR-Associated ATP-Binding Cassette Transporter ABCG2
BCR-ABL1 Compound Mutants Display Differential and Dose-Dependent
Ba/F3 KIF5B-RET
Kinase Profiling of Liposarcomas Using Rnai and Drug Screening Assays
Ponatinib (Iclusig®) EOCCO POLICY
New Oncology Reimbursements in Belgium
Ponatinib and Other CML Tyrosine Kinase Inhibitors in Thrombosis
Ponatinib Inhibits Proliferation and Induces Apoptosis of Liver Cancer Cells, but Its Efficacy Is Compromised by Its Activation on PDK1/Akt/Mtor Signaling
Cancer Drug Costs for a Month of Treatment at Initial Food and Drug
© Ferrata Storti Foundation
Phase III EPIC Trial of Ponatinib Versus Imatinib in Newly Diagnosed CML in Chronic Phase
Ponatinib Inhibits Polyclonal Drug-Resistant KIT Oncoproteins and Shows Therapeutic Potential in Heavily Pretreated Gastrointestinal Stromal Tumor (GIST) Patients
203469Orig1s000
A Cellular Screen Identifies Ponatinib and Pazopanib As Inhibitors of Necroptosis
Pazopanib: Drug Information
Ponatinib Hydrochloride
Cardiovascular Toxicity of Tyrosine Kinase Inhibitors Used in Chronic Myeloid Leukemia: an Analysis of the FDA Adverse Event Reporting System Database (FAERS)
An Oral Tyrosine Kinase Inhibitor for the Treatment of Chronic Myelogenous
ICLUSIG Safely and Effectively
Recent Studies on Ponatinib in Cancers Other Than Chronic Myeloid Leukemia
Tumor Associated Fibroblasts Promote HER2-Targeted Therapy Resistance Through FGFR2 Activation
ICLUSIG Safely and Effectively
Ponatinib—A Step Forward in Overcoming Resistance in Chronic Myeloid Leukemia
January 2021 New Drugs
Ponatinib Is Active Against Imatinib-Resistant Mutants of FIP1L1-PDGFRA and KIT, and Against FGFR1-Derived Fusion Kinases
A High-Content Screening of Anticancer Compounds Suggests
ICLUSIG (Ponatinib) Tablets
Anti-Leukemic Activity of Axitinib Against Cells Harboring the BCR
HOPA News Volume 10, Issue 3, 2013
Committee for Medicinal Products for Human Use (CHMP) Agenda for the Meeting on 23-26 March 2020 Chair: Harald Enzmann – Vice-Chair: Bruno Sepodes
Pharmacological Research the Role of Small Molecule Kit Protein-Tyrosine
Ponatinib (Iclusig) Reference Number: ERX.SPMN.22 Effective Date: 07/16 Coding Implications Last Review Date: 06/16 Revision Log
Ponatinib Open Access to Scientific and Medical Research DOI: 189391
Tyrosine Kinase Inhibitor Associated Vascular Toxicity in Chronic Myeloid